Microba Life Sciences Limited · ASX:MAP
Microba Life Sciences — Investor Presentation (April 2022)
45 slides from Microba Life Sciences's investor presentation, Apr 6, 2022
Slide 1: Precision Microbiome Science
For personal use only Precision Microbiome Science April 2022 This presentation has been authorised for release by the Board.
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of this Presentation, being 30 March 2022. Microba may
Slide 3: Presenters
Presenters For personal use only Dr Luke Reid Prof. Phil Hugenholtz Prof. Gene Tyson Pasquale Rombola Chief Executive Officer Co-Founder and Chair of Co-Founder, Chairman Scientific Advisory Board Non-Executive Director 3
Slide 4: Investment Highlights
Investment Highlights For personal use only World-leading technology in the Partnerships with market leaders Large, unique, proprietary emerging US$4.89 billion incl. SYNLAB (GR:SYAB), Illumina microbiome databank microbiome sector1 (NASDAQ: ILMN), and Genova Diagnostics Lead drug candidate for Canc
Slide 5: Microba's Commercial Model
Microba’s Commercial Model Global testing services build a proprietary databank driving transformative novel therapies For personal use only Services Databank Therapeutics Proprietary databank Data Insights Health Data Customer Novel Testing Biome Data Therapies Microba provides testing Data-driven
Slide 6: Commercial Model: Services
Commercial Model For personal use only SERVICES Global microbiome testing services powered by Microba’s world-leading gut microbiome Analysis Platform Distribution Model Distribution Partners • Partner distribution model scales global access to Existing partners include: the company’s Analysis Platf
Slide 7: Therapeutics
Therapeutics For personal use only THERAPEUTICS Developing novel monoclonal microbial cell therapies through Microba’s data-driven Therapeutics Platform Inflammatory Bowel Cancer Autoimmune Disease Immunotherapy Disease • Potent novel drug candidates • Discovery program initiated • Agreement with Gi
Slide 8: Three major agreements recently executed
Three major agreements recently executed For personal use only Three new international agreements accelerating Microba’s growth trajectory Dec 2021 Feb 2022 Jan 2022 NYSE: DNA | Market cap $5.4B1 Leading US Gastrointestinal Leading Health-Tech Company Pathology Company with laboratory headquartered
Slide 9: Department of Defence Agreement
Department of Defence Agreement Soldier Cognitive Performance Program For personal use only Therapeutic Discovery Opportunity • Developing a globally unique dataset on a large cohort of soldiers linking gut microbiome and cognitive performance data • Targeting the identification of microbial signatu
Slide 10: Microba Board and Senior Management
Microba Board and Senior Management World class team with diverse skills across science, medicine and technology commercialisation For personal use only Dr Luke Reid Pasquale Rombola Prof. Ian Frazer Prof Gene Tyson Prof. Phil Hugenholtz Chief Executive Officer Chairman Deputy Chairman and Co-Founde
Slide 11: Opportunity Overview
For personal use only Opportunity Overview Resolving chronic disease with Precision Microbiome Science 11
Slide 12: World-leading microbiome analysis technology
Other Microba Technology Technology For personal use only World-leading microbiome analysis technology unlocks routine testing and microbiome therapies up to 95% coverage1 up to 34x more accurate2 Published in 1 Calculated by analysing more than 10k samples across Microba’s databank Illustrative vis
Slide 13: The gut microbiome plays a key role in health & disease
The gut microbiome plays a key role in health & disease For personal use only What is the gut microbiome? Modifying the The community of microorganisms that inhabit gut microbiome; the lower digestive tract containing trillions of microbial cells known as the gut microbiome. a key missing piece to r
Slide 14: Microbiome science is changing medicine
Microbiome science is changing medicine and will transform chronic disease management For personal use only Microbiome therapy to treat Microbiome testing to match patients chronic diseases with the right treatment Microbiome modulating primary and adjuvant Microbiome biomarkers and signatures are b
Slide 15: Microbiome Services
For personal use only Microbiome Services Driving global revenues and data growth 15
Slide 16: Services Overview
Services Overview For personal use only • Powered by Microba’s leading microbiome Analysis Platform. • Distribution partners in US, EU & AU offer a microbiome test to their existing customer base with Microba technology. • Key distribution partners established including Synlab (EU), Genova Diagnosti
Slide 17: Partner distribution model
Partner distribution model Scalable global testing services For personal use only Testing Report Data Insights Customer Digital health sample collection Scalable cloud infrastructure report delivery 17
Slide 18: Genova Diagnostics US Distribution Partnership
Dec 2021 Genova Diagnostics US Distribution Partnership Driving US expansion and revenue growth For personal use only Signed Dec 2021 • Founded in 1986 Launch a Microba powered test to a • Headquartered in North Carolina base of 10,000 healthcare providers • Leading gastrointestinal pathology co
Slide 19: G42 Middle East Distribution Partnership
Feb 2022 G42 Middle East Distribution Partnership International expansion and revenue growth For personal use only Signed Feb 2022 • Headquartered in Abu Dhabi, UAE Launch a Microba powered test to • Leading health-tech company consumers and healthcare practitioners • Recently raised US $800m le
Slide 20: Global distribution partners
Global distribution partners Distribution agreements executed with global market leaders to distribute microbiome testing solutions For personal use only powered by Microba’s world leading Analysis Platform technology. TO BE ANNOUNCED AU & NZ US Europe US Middle East AU • Metagenics is a leader in •
Slide 21: Microbiome Databank
For personal use only Microbiome Databank Driving therapeutic discovery 21
Slide 22: Large, unique, proprietary databank
Large, unique, proprietary databank driving multiple therapeutic opportunities For personal use only Revealing disease signatures Already producing novel therapeutic leads across 18 diseases Proprietary Depression Parkinson’s Disease Databank 18 16 Diseases 15K 1.2M 11.7M 13 13 samples genomes genes
Slide 23: Microbiome Therapeutics
For personal use only Microbiome Therapeutics Developing novel monoclonal microbial cell therapies 23
Slide 24: Therapeutics Overview
Therapeutics Overview For personal use only • Strategy is to leverage our proprietary databank to develop multiple therapeutic opportunities and partner with large pharma companies • Human first, data-driven approach to drug discovery is highly sought after by pharmaceutical companies. • Flagship pr
Slide 25: Data-driven platform discovering novel monoclonal microbial cell therapies
Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies For personal use only Monoclonal Population Identify AI & Advanced Disease microbial testing groups Biostatistics Models drug lead Healthy Orally administered, healthy Disease human donor derived, monocl
Slide 26: Inflammatory Bowel Disease program
Inflammatory Bowel Disease program delivering potent orally delivered monoclonal microbial cell therapy For personal use only Healthy + Vehicle DSS + Vehicle Histopathological score Epithelial injury Inflammation score 20 ✱✱ ✱✱✱ 6 10 ✱✱ Histological score (/17) Histological score (/6) Histological s
Slide 27: Repeatable human first, data-driven therapeutic platform
Repeatable human first, data-driven therapeutic platform Demonstrating rapid translation from data to first in human For personal use only CANDIDATE SELECTION PROCESS 25 bacteria 4,784 Bacteria observed Many bacteria differentially prioritised based in Microba dataset abundant in health vs IBD on si
Slide 28: Cancer program
Cancer program Developing a microbiome-derived cancer immunotherapy For personal use only Development partners Developing breakthrough microbiome- derived cancer immunotherapy together with leading Cancer Centers across US and AU. • Between 42% - 70% of patients do not respond to ICI therapy1,2 • Mo
Slide 29: Ginkgo Bioworks Autoimmune Drug Discovery Program
GINKGO BIOWORKS Autoimmune Drug Discovery Program For personal use only “Synthetic biology will transform how we grow food, what we eat, and where we source materials and medicines.” NYSE: DNA | Market cap $5.4B* | Boston HQ Nature Communications, 2020 • Boston based, NYSE listed. • Leader in Synthe
Slide 30: Ginkgo Bioworks Autoimmune Drug Discovery Program
GINKGO BIOWORKS Autoimmune Drug Discovery Program For personal use only Investment • Ginkgo invested US $3.5m into Microba’s IPO* • Ginkgo will become a ~4% shareholder of Microba. Drug Discovery • Microba & Ginkgo will leverage existing Ginkgo synthetic biology capabilities and Microba’s data drive
Slide 31: Therapeutic pipeline
Therapeutic pipeline Repeatable, capital light therapeutic platform For personal use only Inflammatory Bowel Cancer Autoimmune Disease Immunotherapy Disease • US $19.2B market size with • Between 42% - 70% of patients • US $53B market size with 4.8% CAGR1 do not respond to ICI therapy2,3 11.2% CAGR5
Slide 32: Growth sector with big pharma engaged
Growth sector with big pharma engaged For personal use only NASDAQ: MCRB US $1.5B transaction US $534M transaction US $1.9B transaction Agreement to identify biomarkers Agreement to discover biomarker Agreement to commercialise associated with Gilead compounds signatures of drug response, new Seres
Slide 33: Summary
Summary For personal use only Building the leading microbiome testing company Globally scalable distribution partner model with strong growth prospects post COVID Large, unique, proprietary databank Driving multiple therapeutic opportunities Repeatable, scalable drug development platform Gener
Slide 34: Additional information & Risks
For personal use only Additional information & Risks 34
Slide 35: Income Statement
Income Statement For personal use only FY20 FY21 H1 FY21 H1 FY22 (Actual) (Actual) (Actual) (Actual) (‘000) (‘000) (‘000) (‘000) For the financial years ending 30 June Commentary Revenue 2,909 3,732 1,693 2,199 Cost of sales (1,723) (1,668) (797) (1,026) • Healthy and scalable gross margin. Gross Pr
Slide 36: Proforma Balance Sheet – December (H1 FY22)
Proforma Balance Sheet – December 31 (H1 FY22) Pro Forma Balance Sheet For personal use only For the period ended 31 December 2021 $’000 Cash & cash equivalents 32,666 Commentary Financial assets (at amortised cost)1 5,027 • Strong Balance Sheet with minimal debt Receivables 2,233 and a healthy cash
Slide 37: Proforma Cash Flow Statement
Proforma Cash Flow Statement For personal use only Commentary FY20 (Pro Forma) FY21 (Pro Forma) H1 FY21 (Pro Forma) H1 FY22 (Pro Forma) (‘000) (‘000) (‘000) • Strong cash receipts collections from (‘000) customers. For the financial years ending 30 June Receipts from customers 3,922 3,091 1,172 1,92
Slide 38: Risks
Risks Introduction The business, assets and operations of Microba are subject to certain risk factors that have the potential to influence operating and financial performance in the future. These risks can For personal use only impact on the value of an investment in Microba. The Board aims to manag
Slide 39: Risks
Risks Access to sequencing technology, sufficient commercial manufacturing capability, and cloud infrastructure Microba’s testing services (including Microba Insight™ and MetaBiome) are dependent on: For personal use only • uninterrupted operation of the sequencing machine provided and maintained by
Slide 40: Risks
Risks Liquidity and realisation risk Restriction obligations (escrow) have been applied to a number of Shares held by existing Shareholders. The remaining “free float” (shares that are tradable during any restriction period) For personal use only may be limited, resulting in a decrease in active or
Slide 41: Contact
Contact For personal use only Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Simon Hinsley Laboratory Princess Alexandra Hospital Investor / Media Relations Woolloongabba QLD Australia simon@nwrcommunicatons.com.au
Slide 42: Appendix
For personal use only Appendix 42
Slide 43: Board of Directors
Board of Directors For personal use only Pasquale Rombola Prof. Ian Frazer Dr Caroline Popper Prof Gene Tyson Dr Hyungtae Kim Richard Bund Chairman Deputy Chairman and Non-Executive Co-Founder, Non-Executive Director Non-Executive Director Non-Executive Director Chair Medical Advisory Board Director
Slide 44: Medical Advisory Board
Medical Advisory Board For personal use only Prof. Ian Frazer Dr Jakob Begun Dr Paul Griffin Dr Chris Hogan Prof Maria Abreu Prof Jean-Frederic Colombel Deputy Chairman and Medical Advisory Board, Medical Advisory Board, Medical Advisory Board, IBD Advisory Panel Member, IBD Advisory Panel Member, C
Slide 45: Executive Summary
Executive Summary • Company formed in 2017 to acquire co-founder developed IP • Large proprietary databank drives the discovery of multiple from the University of Queensland therapeutic assets For personal use only • 20,000+ microbiome test reports sold to date • Lead drug candidate for Inflammatory
Microba Life Sciences — Investor Presentation (April 2022) on 6ix